Balance Labs, Inc.
BLNC · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.00 | 1.90 | 0.25 |
| FCF Yield | 0.00% | 1.14% | -0.49% | -0.97% |
| EV / EBITDA | -274.37 | -65.07 | 55.32 | 2,919.35 |
| Quality | ||||
| ROIC | 2.51% | 3.00% | 3.12% | 2.52% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.35 | 3.54 | 0.38 | 0.22 |
| Growth | ||||
| Revenue 3-Year CAGR | 59.80% | 17.75% | 0.67% | -9.47% |
| Free Cash Flow Growth | 0.00% | 263.49% | 49.32% | -3.04% |
| Safety | ||||
| Net Debt / EBITDA | -1.31 | -28.79 | 19.71 | 1,033.98 |
| Interest Coverage | 3.47 | -1.40 | -1.39 | -1.14 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -3,254.92 | -2,969.85 | -1,684.80 |